Literature DB >> 26718939

Clinical characteristics and pertussis costs in cases reported to epidemiological services and cases detected in household contacts in Catalonia (Spain).

P Plans1,2, C Muñoz-Almagro3, P Godoy4,5, M Jané4,5, G Carmona4.   

Abstract

PURPOSE: To assess the clinical characteristics and direct health costs associated with pertussis cases reported to and confirmed by epidemiological services and cases detected among household contacts in Catalonia (Spain) in 2012-2013.
METHODS: All pertussis cases confirmed by the epidemiological services (n = 641) and all cases detected among the household contacts (n = 422) were included in the study. The chi-square test and odds ratios were used to compare percentages and the t-test was used to compare mean pertussis costs, with p < 0.05 being considered statistically significant.
RESULTS: Cases reported to epidemiological services had a higher percentage of hospitalizations (OR = 32.2, p < 0.001) and severe disease (OR = 27.7, p < 0.001) than cases detected among the household contacts. The total health costs associated with pertussis cases were €871,648, €799,704 (92 %) for cases reported to epidemiological services and €71,944 (8 %) for cases detected among the household contacts. Total treatment, detection, and quimiprophylaxis costs were € 809,702, € 44,312, and € 17,635, representing 92.5 %, 5.5 %, and 2 % of total pertussis costs respectively. The mean costs were significantly higher (p < 0.001) in cases reported to epidemiological services than in cases detected among the household contacts, for all cases (€1248 vs €170), and for severe (€4546 vs €1073), moderate (€204 vs €165), and mild (€153 vs €133) disease.
CONCLUSIONS: The burden of pertussis in Catalonia was high in terms of health costs, especially in infants aged less than 1 year. Active epidemiological surveillance activities could prevent pertussis transmisison and reduce pertussis costs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26718939     DOI: 10.1007/s10096-015-2542-3

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

1.  Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica.

Authors:  Julian Parkhill; Mohammed Sebaihia; Andrew Preston; Lee D Murphy; Nicholas Thomson; David E Harris; Matthew T G Holden; Carol M Churcher; Stephen D Bentley; Karen L Mungall; Ana M Cerdeño-Tárraga; Louise Temple; Keith James; Barbara Harris; Michael A Quail; Mark Achtman; Rebecca Atkin; Steven Baker; David Basham; Nathalie Bason; Inna Cherevach; Tracey Chillingworth; Matthew Collins; Anne Cronin; Paul Davis; Jonathan Doggett; Theresa Feltwell; Arlette Goble; Nancy Hamlin; Heidi Hauser; Simon Holroyd; Kay Jagels; Sampsa Leather; Sharon Moule; Halina Norberczak; Susan O'Neil; Doug Ormond; Claire Price; Ester Rabbinowitsch; Simon Rutter; Mandy Sanders; David Saunders; Katherine Seeger; Sarah Sharp; Mark Simmonds; Jason Skelton; Robert Squares; Steven Squares; Kim Stevens; Louise Unwin; Sally Whitehead; Bart G Barrell; Duncan J Maskell
Journal:  Nat Genet       Date:  2003-08-10       Impact factor: 38.330

2.  Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage.

Authors:  Pedro Plans-Rubió
Journal:  Hum Vaccin Immunother       Date:  2012-02-01       Impact factor: 3.452

Review 3.  Duration of immunity against pertussis after natural infection or vaccination.

Authors:  Aaron M Wendelboe; Annelies Van Rie; Stefania Salmaso; Janet A Englund
Journal:  Pediatr Infect Dis J       Date:  2005-05       Impact factor: 2.129

4.  Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines.

Authors:  Tejpratap Tiwari; Trudy V Murphy; John Moran
Journal:  MMWR Recomm Rep       Date:  2005-12-09

5.  Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-05-02

6.  Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.

Authors:  Lennart Gustafsson; Luc Hessel; Jann Storsaeter; Patrick Olin
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

7.  Economic impact of pertussis.

Authors:  M E Pichichero; J Treanor
Journal:  Arch Pediatr Adolesc Med       Date:  1997-01

8.  The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children.

Authors:  C D Christie; M L Marx; C D Marchant; S F Reising
Journal:  N Engl J Med       Date:  1994-07-07       Impact factor: 91.245

9.  Prevalence of antibody to Bordetella pertussis in neonates and prevalence of recent pertussis infection in pregnant women in Catalonia (Spain) in 2003 and 2013.

Authors:  Pedro Plans; Elena Álvarez; Fernando de Ory; Magda Campins; Toni Payà; Pilar Balfagón; Pere Godoy; Joan Caylà; Ramon Carreras; Lluís Cabero; Angela Domínguez
Journal:  Pediatr Infect Dis J       Date:  2014-11       Impact factor: 2.129

10.  Hospitalization for pertussis: profiles and case costs by age.

Authors:  Judith A O'Brien; J Jaime Caro
Journal:  BMC Infect Dis       Date:  2005-07-11       Impact factor: 3.090

View more
  2 in total

1.  Effectiveness of acellular pertussis vaccination during childhood (<7 years of age) for preventing pertussis in household contacts 1-9 years old in Catalonia and Navarra (Spain).

Authors:  P Plans; D Toledo; M R Sala; N Camps; M Villanova; R Rodríguez; J Alvarez; R Solano; M García-Cenoz; I Barrabeig; P Godoy; S Minguell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-09       Impact factor: 3.267

2.  Exploring the nasopharyngeal microbiota composition in infants with whooping cough: A test-negative case-control study.

Authors:  Muntsa Rocafort; Desiree Henares; Pedro Brotons; Irene Barrabeig; Cristian Launes; Lore Merdrignac; Marta Valenciano; Angela Domínguez; Pere Godoy; Carmen Muñoz-Almagro
Journal:  PLoS One       Date:  2021-10-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.